Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

INO stock has tumbled in the past few months. Inovio needs the FDA to bail it out by allowing the advanced trials of its vaccine to begin.

Inovio Pharmaceutical's FDA Plight Makes It a Highly Risky Bet

Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Monday the lifting of the FDA-imposed partial clinical hold on the start of the Phase 2 study of INO-4800, its DNA coronavirus vaccine candidate.  The Inovio Analyst: Roth Capital Partners analyst Jonathan Aschoff downgraded Inovio from Neutral to Sell and maintained an $8 price target.

Inovio Analyst: COVID-19 Competition Could Be Too Great

The FDA recently lifted the clinical hold on Inovio's Covid-19 vaccine candidate. The result could mean huge returns for INO stock.

The Clock Is Ticking for Inovio Stock

One analyst thinks you should sell the biotech's shares.

Why Inovio Stock Plunged Today

Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.

Inovio Has Little to Show for Its Covid-19 Efforts

The biotech delivered good news regarding its coronavirus vaccine program.

Why Inovio Pharmaceuticals Stock Is Jumping Today

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares soared on Monday after the company provided an update for its coronavirus vaccine candidate.

Inovio Pharma to Move Forward With COVID-19 Vaccine Candidate

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are higher after an update issued by the company on its investigational coronavirus vaccine. What Happened: Pennsylvania-based Inovio said the FDA has issued clearance for the commencement of the Phase 2 segment of the Phase 2/3 study of its DNA vaccine candidate, codenamed INO-4800, against SARS-CoV-2.

FDA Lifts Partial Clinical Hold On Inovio's Phase 2 Investigational Coronavirus Vaccine Study

INO stock is a purely speculative bet. I don't see the company being among the few that deliver a vaccine against Covid-19.

At This Point, Go Ahead and Count Inovio Pharmaceuticals Out of the Vaccine Race

Regeneron Pharmaceuticals

These companies are capitalizing on the market's interest in combating the coronavirus.

Better Coronavirus Stock: Inovio Pharmaceuticals or Regeneron?

Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Inovio (INO) Stock?

Shares of Inovio (NASDAQ:INO) are trading near a six-month low. The company is being battered by delays in getting its Covid-19 vaccine candidate into Phase 2 trials.

Can Inovio Benefit From All Of Its Vaccine Delays?

Inovio has thrown its hat into the coronavirus vaccine ring with big biopharma names like Moderna, Johnson & Johnson and Pfizer. But INO stock is volatile on its vaccine news.

Should Inovio Be On Your Buy List As It Tackles A Coronavirus Vaccine?

AstraZeneca

Johnson & Johnson

Moderna

Pfizer

BioNTech SE

Investors are setting themselves up for disappointment.

5 Reasons Chasing COVID-19 Vaccine Stocks Is a Bad Idea

Hint: It wasn't the company's top and bottom lines.

What Really Mattered With Inovio's Q3 Update

Inovio Pharmaceuticals, Inc. (INO) CEO J. Joseph Kim on Q3 2020 Results - Earnings Call Transcript

Shares of Inovio Pharmaceuticals (NASDAQ:INO) increased 2.94% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 4.00% year over year to ($0.26), which missed the estimate of ($0.19).

Recap: Inovio Pharmaceuticals Q3 Earnings

PLYMOUTH MEETING, Pa., Nov. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended...

INOVIO Reports Third Quarter 2020 Financial Results

Coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO)'s stock, which was rocked in September by the partial clinical hold imposed on the planned Phase 2/3 study of the company's DNA vaccine INO-4800, is facing further pressure Monday. What Happened: Inovio shares are reacting to announcements from rival vaccine developers Novavax, Inc. (NASDAQ: NVAX) and the Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) partnership.

Inovio Plunges To 7-Month Low On Updates From Rival COVID-19 Vaccine Developers

Novavax

Vaxart

These three pre-revenue COVID-19 vaccine stocks took a beating last month.

Why Inovio Pharmaceuticals, Novavax, and Vaxart Crashed in October

The fate of this company's late-stage trial is now in the hands of the FDA.

November Is a Crucial Month for this Coronavirus Vaccine Stock

Beware the risks of investing in this small-cap COVID-19 vaccine developer.

3 Red Flags for Inovio Pharmaceuticals' Future

Inovio Pharmaceuticals (NASDAQ: INO) releases its next round of earnings this Monday, November 09. Get the latest predictions in Benzinga's essential guide to the company's Q3 earnings report.

Inovio Pharmaceuticals's Earnings: A Preview

These companies aren't about to win the coronavirus vaccine race, but their competitors probably will.

Avoid These 2 Coronavirus Innovator Stocks in November

Inovio Pharmaceuticals Inc (NASDAQ: INO) responded to the FDA's questions about INO-4800 and the Cellectra vaccine delivery device in October, the company confirmed to Benzinga. Inovio Continues Phase 2/3 Trial Prep: The FDA imposed a partial clinical hold in September on the planned Phase 2/3 clinical study of INO-4800, its DNA vaccine candidate against the novel coronavirus.

News for Inovio Pharmaceuticals Stock (INO)